These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
502 related articles for article (PubMed ID: 14969166)
41. Efficacy and acceptability of depo-medroxyprogesterone acetate injection. As a method of contraception in Saudi Arabia. Sobande AA; Al-Bar HM; Archibong EI; Sadek AA Saudi Med J; 2000 Apr; 21(4):348-51. PubMed ID: 11533816 [TBL] [Abstract][Full Text] [Related]
42. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report. Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754 [TBL] [Abstract][Full Text] [Related]
43. Depo-Provera -- proving its innocence. Choudhury IR Indian Med Trib; 1994 Jul; 2(11):5. PubMed ID: 12179187 [TBL] [Abstract][Full Text] [Related]
44. Exposure to DMPA in pregnancy may cause low birth weight. Prog Hum Reprod Res; 1992; (23):2-3. PubMed ID: 12286194 [TBL] [Abstract][Full Text] [Related]
45. The contraceptive use of depot medroxyprogesterone acetate. Hickey M; Fraser I Clin Obstet Gynecol; 1995 Dec; 38(4):849-58. PubMed ID: 8616981 [TBL] [Abstract][Full Text] [Related]
46. Contraceptive efficacy and safety of DMPA-SC. Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329 [TBL] [Abstract][Full Text] [Related]
47. Injectable medroxyprogesterone. Rosenfield AG Drug Ther (NY); 1975 Jul; 5():139. PubMed ID: 12229496 [TBL] [Abstract][Full Text] [Related]
48. Injectable contraception. Roy G Semin Reprod Med; 2010 Mar; 28(2):126-32. PubMed ID: 20352562 [TBL] [Abstract][Full Text] [Related]
49. Injectable contraceptives: how safe are they? Initiatives Popul; 1979; 5(4):2-10. PubMed ID: 12338524 [TBL] [Abstract][Full Text] [Related]
50. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. Beksinska ME; Smit JA; Kleinschmidt I; Farley TM; Mbatha F Contraception; 2005 Mar; 71(3):170-5. PubMed ID: 15722065 [TBL] [Abstract][Full Text] [Related]
51. Injectable contraceptives: underused and undervalued? Parker C Prof Care Mother Child; 1997; 7(4):95-7. PubMed ID: 9348967 [TBL] [Abstract][Full Text] [Related]
52. The future for injectable contraceptives. Rutter T Afr Health; 1993 Mar; 15(3):18-9. PubMed ID: 12344840 [TBL] [Abstract][Full Text] [Related]
53. Demographic analysis of post-abortive and interval-administered hormonal contraceptive methods. Ertopçu K; Inal MM; Ozelmas I Eur J Contracept Reprod Health Care; 2005 Mar; 10(1):1-5. PubMed ID: 16036290 [TBL] [Abstract][Full Text] [Related]
55. The use of depot medroxyprogesterone acetate (DMPA) injectable contraceptive in Enugu, Nigeria. Hu E; Ikeako LC; Obiora-Okafor NC Niger J Med; 2012; 21(3):266-71. PubMed ID: 23304918 [TBL] [Abstract][Full Text] [Related]
56. Depot medroxyprogesterone acetate: implications for weight status and bone mineral density in the adolescent female. Bonny AE; Harkness LS; Cromer BA Adolesc Med Clin; 2005 Oct; 16(3):569-84. PubMed ID: 16183540 [TBL] [Abstract][Full Text] [Related]
57. Bone density in long term users of depot medroxyprogesterone acetate. Gbolade B; Ellis S; Murby B; Randall S; Kirkman R Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421 [TBL] [Abstract][Full Text] [Related]
58. Experience with the use of depo-medroxyprogesterone acetate in a Nigerian population. Falase EA; Otolorin EO; Ladipo OA Afr J Med Med Sci; 1988 Dec; 17(4):209-13. PubMed ID: 2854367 [TBL] [Abstract][Full Text] [Related]
59. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Clark MK; Sowers MR; Nichols S; Levy B Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863 [TBL] [Abstract][Full Text] [Related]